Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death
- 31 August 2004
- Vol. 136 (2) , 416-425
- https://doi.org/10.1016/j.surg.2004.05.018
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Combined proteasome and histone deacetylase inhibition in non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2004
- P-338 Proteosome inhibition sensitizes NSCLC to generation of reactive oxygen species and cell deathLung Cancer, 2003
- Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis Involves the Transcriptional Activation of NF-κB through the Akt PathwayJournal of Biological Chemistry, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002
- Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38Journal of Biological Chemistry, 2001
- Inhibition of NF-κB sensitizes non–small cell lung cancer cells to chemotherapy-induced apoptosisThe Annals of Thoracic Surgery, 2000
- The IκB kinase (IKK) and NF-κB: key elements of proinflammatory signallingSeminars in Immunology, 2000
- Novel Inhibitors of Cytokine-induced IκBα Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in VivoJournal of Biological Chemistry, 1997
- THE NF-κB AND IκB PROTEINS: New Discoveries and InsightsAnnual Review of Immunology, 1996